Epitalon (10 mg vial)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

Frequency: one subcutaneous injection per day during a course, taken in the evening 1 to 2 hours before bed so the dose lines up with the pineal mechanism and the natural melatonin rhythm. A course runs 10 consecutive days at 10 mg or 20 consecutive days at 5 mg, and repeats every 4 to 6 months for longevity protocols or annually for maintenance, which puts most research use at 2 to 4 courses per year. The Khavinson original pattern is intermittent instead: 10 mg every third day for 5 injections, a 50 mg course total. Higher doses, tested up to 50 mg per day, show no additional benefit beyond the standard range, and the low concentration activity pattern, with optimal in vitro activity near 10 ng/mL, suggests epigenetic signaling rather than direct enzyme saturation, so short courses trigger lasting gene expression changes that persist after the peptide clears. No tolerance has been reported with cycled use. At 10 mg/mL a 10 mg dose is exactly 100 units (1.0 mL) and a 5 mg dose is 50 units (0.50 mL), so every dose in this protocol fits one U-100 insulin syringe and none of them need splitting across two injections. Sites are rotated systematically across abdomen, thighs, and upper arms.

Results Timeline

Sequence described in the research record. Individual response varies.

• Days 1 to 10 at 10 mg daily, or days 1 to 20 at 5 mg daily: the active course, dosed each evening 1 to 2 hours before bed.
• First nights: vivid dreams from REM enhancement, mild transient headache, or occasional drowsiness may appear, and sleep disruption is reported rarely; these are described as resolving within days.
• Weeks 1 to 2: improved subjective sleep quality is the most consistently reported near-term effect and the earliest indication the mechanism is active. No visible skin or hair changes are expected.
• After the course ends: effects are described as persisting between courses, because the peptide triggers epigenetic changes rather than overriding a continuous signal.
• Months 4 to 6: the next course begins, or the interval stretches to a year on a maintenance pattern.

Reconstitution Steps

1. Draw 1.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl until dissolved (do not shake).
4. Label with date and concentration; refrigerate at 2 to 8 °C, protected from light. At 10 mg/mL, 1 unit = 0.01 mL » 100 mcg on a U-100 insulin syringe, so 5 mg = 50 units (0.50 mL) and 10 mg = 100 units (1.0 mL), each of which fits a single U-100 syringe.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: stable 3 years or longer frozen at -20 °C, and 6 to 12 months refrigerated at 2 to 8 °C. Protect from light.
• Reconstituted: refrigerate at 2 to 8 °C; stable about 6 weeks with bacteriostatic water; avoid freeze-thaw.

• Allow vials to reach room temperature before opening to reduce condensation uptake.
• At 1.0 mL per vial, one reconstituted vial covers a single 10 mg dose or two 5 mg doses, so on the 20 day course a vial is opened every second day and the 6 week window is never the limiting factor.

Supplies Needed

Planning below is based on one 100 mg course, either 10 days at 10 mg per day, which is 70 mg in a full week, or 20 days at 5 mg per day, which is 35 mg in a full week.

Peptide Vials (Epitalon, 10 mg vial):

• A full course is 100 mg either way, which is 10 vials of 10 mg; the Khavinson intermittent course totals 50 mg, or 5 vials, and an annual budget of 2 courses is about 20 vials.

Insulin Syringes (U-100):

• Per week: 7 U-100 insulin syringes at one injection daily, since at 10 mg/mL a 10 mg dose is 100 units (1.0 mL) and a 5 mg dose is 50 units (0.50 mL), so one syringe covers either.
• Full course: 10 syringes for the 10 day course at 10 mg, 20 for the 20 day course at 5 mg, and 5 for the Khavinson intermittent course.

Bacteriostatic Water (10 mL bottles):

• Each 10 mg vial takes 1.0 mL of bacteriostatic water, so one 10 mL bottle covers 10 vials, which is a complete 100 mg course.

Alcohol Swabs:

• Per injection: 2 alcohol swabs, one for the vial stopper and one for the skin.
• Full course: 20 swabs across the 10 day course and 40 across the 20 day course, so one 100 count box covers about 2 courses.

Important Notes

Practical considerations for consistency and safety.

• Cycled, not continuous. Courses run 10 to 20 days every 4 to 6 months, and continuous daily use has not been studied. The short course structure reflects how the mechanism works: a burst of telomerase activity and melatonin normalization, with effects persisting between courses.
• Evening dosing matters. The pineal mechanism aligns with the natural circadian rhythm, so morning dosing wastes the timing advantage. Sleep quality within 1 to 2 weeks is the near-term signal that the mechanism is active.
• Cancer contraindication. Telomerase activation is a theoretical concern in active or suspected malignancy. The 2025 Brunel study showed Epitalon triggers a different pathway, ALT, in cancer cells rather than supporting telomerase, but that has not been clinically validated, and the compound is not used in active malignancy.
• Other contraindications: pregnancy or breastfeeding, where there is no safety data; compromised immune function, where the interaction is unknown; and known peptide hypersensitivity.
• Stacking partners named in the master: NAD+ precursors through the CLOCK:BMAL1 to NAMPT to SIRT1 axis, since Epitalon restores the circadian gene expression that regulates NAD+ salvage; MOTS-c and SS-31, where mitochondrial efficiency complements circadian restoration; senolytics such as fisetin or quercetin with dasatinib, to clear cells that are already senescent while Epitalon extends new cellular lifespan; and DSIP for sleep architecture pairing.
• Regulatory Note: Epitalon has been an FDA Category 2 bulk substance since 2024 and cannot be legally compounded in the US, with immunogenicity the cited concern, so only research-grade product labeled not for human use is available in Western markets. A 2025 systematic review states that critical safety information is missing, and long-term safety, immunogenicity, and drug interactions have not been systematically studied. The master sheet records no WADA status for this compound. For research use only; not for human consumption.

How This Works

Epitalon's small size, about 400 Daltons, lets it cross cell membranes and enter the nucleus, where it binds DNA at specific ATTTC sequences in the telomerase gene promoter and upregulates hTERT, the catalytic subunit of telomerase. Measured effects in cell lines run from 4-fold to 26-fold hTERT upregulation with about 33% telomere lengthening in cultured human fibroblasts, and the dose-response is unusual: optimal activity sits near 10 ng/mL, roughly 25 nM, with higher concentrations no more effective. That inverse pattern points to an epigenetic signaling mechanism, which explains why short 10 to 20 day courses produce effects lasting months. The 2025 Brunel University study added a safety insight: in normal cells Epitalon upregulates telomerase as described, while in cancer cells it instead binds H1 histones, de-represses H19, and inhibits telomerase, triggering the ALT (Alternative Lengthening of Telomeres) pathway. Cancer cells carry lower baseline H1 histone levels, which makes them more susceptible to that redirection, and the dual mechanism may explain why animal studies showed reduced tumor incidence despite telomerase activation. Separately, Epitalon stimulates AANAT, the enzyme that converts serotonin toward the melatonin precursor, and pCREB transcription factor expression in aged pineal cells with tissue-specific targeting, restoring melatonin by 1.6-fold in elderly subjects and normalizing clock gene expression across PER1/2, BMAL1, and CLOCK. That connects to broader longevity biology through the CLOCK:BMAL1 to NAMPT to NAD+ to SIRT1 feedback loop: restored circadian gene expression upregulates NAMPT, which is rate limiting for NAD+ salvage, supporting sirtuin activity that feeds back into circadian control.

Benefits & Side Effects

Observations from the published record.

• Telomerase activation, independently confirmed in 2025: hTERT upregulation in normal cells and about 33% telomere lengthening in cultured human fibroblasts. The Brunel study confirmed the mechanism outside Russian research for the first time.
• Differential cancer cell response (2025): in cancer cells Epitalon triggers the ALT pathway rather than telomerase activation, and ALT was not activated in normal cells. Researchers concluded it can be used safely in healthy individuals to maintain telomeres.
• Sleep architecture and melatonin restoration: a 1.6-fold melatonin increase in elderly subjects, normalized PER1/2, BMAL1, and CLOCK expression, and restored cortisol rhythm distinction. Subjective sleep improvement is the most consistently reported user effect, typically within 1 to 2 weeks.
• Animal lifespan data: SHR mice showed maximum lifespan up 12 to 13% for the longest lived 10%, with mean lifespan unaffected, a 6-fold reduction in spontaneous leukemia, and a 17.1% reduction in chromosome aberrations in bone marrow cells.
• Khavinson human claims, unreplicated: a Kiev 15 year study (n=79) reporting 28% lower mortality and 2x lower cardiovascular mortality, combined Thymalin and Epithalamin (n=266) reporting a 4.1-fold mortality reduction, and retinitis pigmentosa (n=162) reporting 90% positive clinical effect. After 40 years and more than 775 publications no independent laboratory has replicated the human findings, the ADDF flagged that gap explicitly, about half of the publications are Russian only, and there are no trials on ClinicalTrials.gov.
• Side effects: mild injection site reactions, which are common; occasional fatigue or drowsiness that often resolves within days; mild transient headaches; vivid dreams from REM enhancement, generally considered positive; and rarely sleep disruption during the initial nights. A 2025 systematic review notes that critical safety information is missing and that long-term safety and immunogenicity have not been systematically studied.

Lifestyle Factors

Complementary strategies for best outcomes.

• Sleep hygiene matters. Epitalon supports the pineal melatonin axis but cannot override poor light exposure, screen use before bed, or irregular schedules, so evening dosing is paired with consistent sleep timing. Morning bright light exposure anchors the circadian system the peptide is trying to restore.
• Limit alcohol during a course, because ethanol disrupts melatonin secretion and works against the mechanism.
• An antioxidant rich diet supports the broader cellular protection picture: cruciferous vegetables, polyphenols, and omega-3s.
• Strength training and general physical activity are independent telomere-protective stimuli, and managing chronic stress matters because chronically elevated cortisol accelerates telomere attrition.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry.
2. Pinch a skinfold; insert the needle at 45 to 90 degrees into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. Wait 5 to 10 seconds before withdrawing; dispose of syringe in sharps container.
5. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.

References

Source citations for further reading.

1. Khavinson VK et al. Peptide promotes telomere elongation and telomerase activity in cultured human cells (Bull Exp Biol Med, 2003).
2. Anisimov VN et al. SHR mice lifespan extension and reduced leukemia incidence (Biogerontology, 2003).
3. Khavinson VK, Linkova NS et al. Epithalon and telomerase activation: implications for longevity (Adv Gerontol, 2018).
4. Brunel University, 2025: dual mechanism, telomerase in normal cells and ALT in cancer cells, the first independent Western confirmation of the cellular mechanism.
5. Alzheimer's Drug Discovery Foundation Cognitive Vitality Report: Epithalamin and Epithalon assessment.
6. Systematic review of the Epitalon safety data gap (Int J Mol Sci, 2025).